Clinical Research

Palo Alto, Calif. – October 01, 2026 -- TurnCare, Inc. reported a 36.2% reduction in total hospital-acquired pressure injuries (HAPIs) among ECMO patients following implementation of its GuardianTM System, according to new clinical data presented at the 37th Annual Extracorporeal Life Support Organization (ELSO) 2026 Conference in Nashville, Tennessee.

Single-center study tracks outcomes across 2,707 ECMO days

The retrospective pre- and post-cohort analysis, conducted at M Health Fairview University of Minnesota Medical Center, compared a baseline group of 317 ECMO patients (327 runs, 2,112 ECMO days) against a Guardian-treated cohort of 92 patients (97 runs, 595 ECMO days). Chris Linke, MHI, RN, CSSMBB, presented the findings.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Highest dose delivers weight loss up to 23.4% in heavier patients

Across the three tested doses, participants lost an average of 29.8 lbs (12.7%) at 4 mg, 45.4 lbs (19.1%) at 9 mg, and 49.6 lbs (20.8%) at 12 mg. Among patients with a baseline BMI of 35 or higher, the 12 mg dose produced an average loss of 60.8 lbs (23.4%), with 59.5% of all 12 mg participants no longer classified as having obesity by trial end.

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Retrospective analysis covers 636,525 patients on semaglutide 1 mg

The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.

Indianapolis – September 29, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 drug Foundayo (orforglipron) at 17.2 mg produced 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg over 52 weeks in adults with type 2 diabetes, based on an indirect treatment comparison presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan.

Indirect analysis draws on ACHIEVE-3 and PIONEER PLUS trial data

The comparison, covariate-adjusted for gender, age, baseline A1C and baseline weight, found weight-loss differences ranging from 1.5% to 2.4% and A1C reductions of 0.3% to 0.6% in favor of Foundayo 17.2 mg across multiple statistical methods. The 95% confidence interval for weight loss was -2.7% to -0.2%, and for A1C reduction was -0.6% to -0.1%.

Shanghai – September 26, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

RD140 achieves 88.9% MRD negativity in high-risk relapsed patients

The investigator-initiated trial (NCT06655519), led by Professor Jin Lu of Peking University People's Hospital, enrolled patients who had failed at least three prior lines of therapy, including two who had previously received BCMA-targeted treatment. All nine patients were triple-class exposed, and six were penta-exposed. As of the September 26, 2026 data cutoff, with a median follow-up of 6.05 months, 88.9% of patients achieved MRD negativity at the 10−5 threshold, with six reaching this benchmark as early as day 28. Median progression-free survival has not been reached.

Shanghai – September 26, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Half of patients reach five-year progression-free survival without maintenance

In the initial subgroup of cohort A (N=20), 10 of 20 patients treated with a single CARVYKTI® infusion remained progression-free at a median follow-up of 60.7 months. Median progression-free survival reached 60.5 months, and the results were presented at the International Myeloma Society Annual Meeting (Abstract #PA-288). Cohort A enrolled patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.

Pune, India – September 25, 2026 -- The global multiple sclerosis treatment market reached USD 26.76 billion in 2025 and is forecast to climb to USD 44.45 billion by 2034, expanding at a 5.8% CAGR, according to a new report from Maximize Market Research.

Disease-modifying therapies and biologics drive current market expansion

Rising MS prevalence, improved diagnostic capabilities, and growing adoption of immunomodulators, immunosuppressants, interferons, oral disease-modifying therapies (DMTs), and monoclonal antibodies are fueling demand across relapsing-remitting (RRMS), primary progressive (PPMS), secondary progressive (SPMS), and clinically isolated syndrome (CIS) patient segments. High-efficacy biologics and oral treatment options are increasingly displacing older therapy classes as patients and physicians prioritize convenience and disease-progression control.

Friendswood, Texas – September 25, 2026 -- More than half of atopic dermatitis (AD) patients who used targeted systemic therapies modified treatment because the drugs failed to work, according to a new study published in Dermatology and Therapy by Castle Biosciences, Inc. (Nasdaq: CSTL).

Study finds 55% of systemic therapy users switched due to lack of efficacy

The research surveyed 43 AD patients and caregivers who completed a 32-question assessment at the 2024 National Eczema Association Eczema Expo. Among respondents who had used targeted systemic therapies, 55% reported modifying treatment because of insufficient results. Inadequate skin clearance and persistent itching were cited as the most frequent reasons for switching drugs or adding topical treatments.

Dover, Del. – September 25, 2026 -- Clywedog Therapeutics, Inc. reported that its investigational menin inhibitor balomenib produced a placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p0.01) and 0.70% at Week 16 (p0.05) in a Phase 1b trial, effects recorded three months after the drug's final dose following just three weeks of treatment.